OKYO PHARMA LTD SP.ADR/65 (OK10) - Net Assets

Latest as of September 2025: €-3.42 Million EUR ≈ $-3.99 Million USD

Based on the latest financial reports, OKYO PHARMA LTD SP.ADR/65 (OK10) has net assets worth €-3.42 Million EUR (≈ $-3.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.64 Million ≈ $5.43 Million USD) and total liabilities (€8.06 Million ≈ $9.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read OK10 total debt and obligations for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-3.42 Million
% of Total Assets	-73.54%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

OKYO PHARMA LTD SP.ADR/65 - Net Assets Trend (2022–2025)

This chart illustrates how OKYO PHARMA LTD SP.ADR/65's net assets have evolved over time, based on quarterly financial data. Also explore how large is OKYO PHARMA LTD SP.ADR/65's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for OKYO PHARMA LTD SP.ADR/65 (2022–2025)

The table below shows the annual net assets of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025. For live valuation and market cap data, see OK10 company net worth.

Year	Net Assets	Change
2025-03-31	€-5.55 Million ≈ $-6.49 Million	+5.61%
2024-03-31	€-5.88 Million ≈ $-6.87 Million	-186.36%
2023-03-31	€-2.05 Million ≈ $-2.40 Million	-169.66%
2022-03-31	€2.95 Million ≈ $3.45 Million	--

Equity Component Analysis

This analysis shows how different components contribute to OKYO PHARMA LTD SP.ADR/65's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 3059893800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Other Components	€137.48 Million	%
Total Equity	€-5.55 Million	100.00%

OKYO PHARMA LTD SP.ADR/65 Competitors by Market Cap

The table below lists competitors of OKYO PHARMA LTD SP.ADR/65 ranked by their market capitalization.

Company	Market Cap
CORESTATE Capital Holding S.A F:CCAP	$38.38 Million
Cobalt Blue Holdings Ltd AU:COB	$38.42 Million
Rothwell International Co. Limited KQ:900260	$38.42 Million
Shengfeng Development Limited Class A Ordinary Shares NASDAQ:SFWL	$38.43 Million
Megastar Foods Limited NSE:MEGASTAR	$38.37 Million
Cowealth Medical Holding Co Ltd TWO:4745	$38.36 Million
Sinmah Capital Bhd KLSE:9776	$38.36 Million
Sheh Kai Precision Co Ltd TWO:2063	$38.34 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in OKYO PHARMA LTD SP.ADR/65's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -5,879,582 to -5,549,555, a change of 330,027.
Net loss of 4,706,292 reduced equity.
New share issuances of 1,705,742 increased equity.
Other factors increased equity by 3,330,577.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€-4.71 Million	-84.8%
Share Issuances	€1.71 Million	+30.74%
Other Changes	€3.33 Million	+60.02%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares OKYO PHARMA LTD SP.ADR/65's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2022-03-31	€0.14	€1.36	x
2023-03-31	€-0.04	€1.36	x
2024-03-31	€-0.18	€1.36	x
2025-03-31	€-0.15	€1.36	x

Capital Efficiency Dashboard

This dashboard shows how efficiently OKYO PHARMA LTD SP.ADR/65 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-46.07%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2022	-184.27%	0.00%	0.00x	1.46x	€-5.73 Million
2023	0.00%	0.00%	0.00x	0.00x	€-13.07 Million
2024	0.00%	0.00%	0.00x	0.00x	€-16.24 Million
2025	0.00%	0.00%	0.00x	0.00x	€-4.15 Million

Industry Comparison

This section compares OKYO PHARMA LTD SP.ADR/65's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $355,224,390
Average return on equity (ROE) among peers: -60.76%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
OKYO PHARMA LTD SP.ADR/65 (OK10)	€-3.42 Million	-184.27%	N/A	$38.38 Million
PROQR THERAPEUTICS EO-04 (0PQ)	$66.68 Million	-96.62%	1.57x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$3.94 Million	-301.40%	1.87x	$161.62 Million
Theravance Biopharma Inc (0TB)	$289.79 Million	-81.80%	0.17x	$823.46 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$230.94 Million	-20.03%	0.13x	$205.51 Million
PreveCeutical Medical Inc (18H)	$-4.49 Million	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$1.36 Billion	-38.77%	0.36x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$-45.09 Million	0.00%	0.00x	$1.14 Billion
BIOCURE TECHNOLOGY INC. (1WH)	$-852.32K	0.00%	0.00x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$1.38 Billion	-51.05%	0.17x	$1.82 Billion
BioNTech SE (22UA)	$267.00 Million	-17.98%	1.45x	$20.05 Billion

About OKYO PHARMA LTD SP.ADR/65

F:OK10 Germany Biotechnology

Market Cap

$44.87 Million

€38.38 Million EUR

Market Cap Rank

#22971 Global

#2028 in Germany

Share Price

€1.36

Change (1 day)

+0.00%

52-Week Range

€1.36 - €1.36

All Time High

€2.84